Chris Garabedian founded Xontogeny in June of 2016 to support multiple promising technologies from early development through clinical proof of concept. In 2017, Chris joined Perceptive Advisors to develop their Venture Fund strategy and is Portfolio Manager of the Perceptive Xontogeny Ventures Fund which supports early stage companies with Series A investments across biotech, medtech and healthtech. Chris has a broad base of experience and a track record of success over his decades long experience in the biopharma industry. Chris served as the President and CEO of Sarepta Therapeutics from 2011 to 2015, overseeing the turnaround of a company that is now a commercial stage leader in the genetic technology space after leading the development of the company’s Duchenne Muscular Dystrophy program. Prior to Sarepta, Chris led Corporate Strategy for Celgene from 2007 to 2010. Prior to Celgene, Chris served in a number of global commercial and corporate development leadership roles at Gilead from 1997 to 2005.

Before founding 1910, Jen worked at the intersection of life science, technology, and business. Prior roles include Management Consultant at Bain & Company, Director of Business Development at a health-tech startup (pre-seed to Series A), and drug discovery stints at Novartis and Eli Lilly. During her Ph.D. research, Jen was an HHMI Predoctoral Fellow at the medical schools of Tufts University and Harvard University.

As President and COO, Kendalle leads the strategic direction, global expansion, and business operations of the organization ensuring that MassBio offers the greatest value to its members and that Massachusetts life sciences companies have the best environment possible to research, develop, and commercialize breakthrough therapies and cures for people around the world who need and deserve them. Kendalle first came to MassBio in 2008 as Director of Purchasing and Strategic Alliance. She was promoted to Vice President of Member Services and General Counsel in 2012, then promoted to the organization’s first-ever Chief Operating Officer in February 2019. Throughout her tenure at MassBio, Kendalle has played a critical role in the growth of MassBio’s membership supporting its expansion to become the largest life sciences trade association in the world with over 1,400 members. Kendalle has overseen the rebrand of a number of MassBio’s core programs and services, including the MassBio Edge, MassBio’s savings and rewards program, and its expansion into other New England states by building valuable partnerships with the supplier community and creating MassBio’s highly-rated Employee Rewards program. She also led the development of the MassBioHub, MassBio’s conference and business center, and the creation of MassBio’s 2025 State of Possible Report. In 2019, Kendalle commenced a multi-year digital health initiative to support the convergence of digital tech and the life sciences in Massachusetts. And in 2021, Kendalle was instrumental in the launch of MassBio’s Partnering Week, a new initiative to bring together established biopharma companies with early-stage startups and academic institutions. Kendalle has reached extraordinary heights in her growing career. She was named a 2019 Boston Business Journal 40 under 40 honoree which recognizes a leader’s impact on Massachusetts’ industries.